Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 28

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 28
---
izes
soluble TNF, and is therefore not immunosuppressive. Additionally, XPro has been shown to cross the blood brain barrier after peripheral
administration, making it attractive for use in treating CNS disorders. The following table summarizes current IP covering our DN-TNF
platform technology:

    Subject Matter / Compound 
    # Pending Applications  
    # Issued Patents  
    Geographical Scope  
    Nominal Patent Term 
  
    DNTNF compositions and formulations 
     2  
     0  
     global  
     2044-2045 
  
    Use of DNTNF for treating disease 
     19  
     10  
     global  
     2033-2041 
  
    DNTNF manufacturing/CMC 
     1  
     0  
     global  
     2045 

INB-16 / INKmune (Oncology)

INKmune is a replication-incompetent
derivative of our proprietary INB-16 cell line. One commercial application of INKmune includes use as a therapeutic composition designed
to enhance the ability of a patient’s own NK cells to seek, recognize and eliminate cancer. Another commercial application of INKmune
includes use as a cytokine-like (“pseudokine”) agent for enhancing NK cell killing specificity, potency, and efficacy of NK
cell -based therapeutics. INKmune, as a therapeutic, is intended for provision as an I.V. -infused product containing replication-incompetent
bio substrate units, each of which is adapted to present an aggregate of protein ligands and/or receptors to a patient’s own NK
cells, in vivo. Upon contacting the patient’s NK cells, INKmune converts resting NK cells into what we call “primed”
NK cells (“pNKs”). Data suggests that pNKs demonstrate enhanced killing of tumor cells, thus INKmune may indirectly improve
a patient’s own immune response to cancer. As a pseudokine agent, INKmune can be used to contact the NK cells of an NK cell therapeutic
product in vitro, e.g., during manufacturing, for enhancing characteristics of the NK cell therapeutic and rendering an improved
product. The following table summarizes current IP covering INB-16 / INKmune:

    Subject Matter / Compound 
    #